Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

A larger role for China, perhaps, and the fraught issue of integrating HIV services into services for other diseases.

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and ...

As science soars with game-changing HIV tools, a funding crisis threatens to ground progress "We come together at a pivotal time for the HIV response, one defined by both incredible scientific ...

In a major advancement in the global fight against HIV, the World Health Organization (WHO) has recommended the use of ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...